First Capital Markets Meeting

RNS Number : 7420X

PureTech Health PLC

10 May 2016

 

10 May 2016

PureTech Health plc

First Capital Markets Meeting

PureTech Health plc ("PureTech", LSE: PRTC), a cross-disciplinary healthcare company tackling fundamental healthcare needs in disruptive ways, is today holding its first Capital Markets Meeting as a London Listed Company. The Company will provide insight into its strategy, progress of the Company's pipeline, and insights into new areas of unmet medical need being explored. No new material information will be disclosed.

The meeting will take place in London from 13.00-17.00 BST and will feature PureTech presenters including members of the Company's Board of Directors. 

Presenters at the event include:

·     Daphne Zohar, Co-Founder & CEO of PureTech

·     Joi Ito, Chairman of the Board of Directors of PureTech; Director of the MIT Media Lab

·     Raju Kucherlapati, PhD, Independent Non-Executive Director, Scientific Advisory Board Member of PureTech; Co-Founder of Millennium Pharmaceuticals and Abgenix

·     John LaMattina, PhD, Independent Non-Executive Director of PureTech; former President of Pfizer Global Research and Development

·     Marjorie Scardino, Senior Independent Director of PureTech; former CEO of The Economist and of Pearson plc, Chairman of the MacArthur Foundation Board

·     Ben Shapiro, MD, Co-Founder & Non-Executive Director of PureTech; former Executive Vice President of Research for Merck

·     Christopher Viehbacher, Independent Non-Executive Director of PureTech; former CEO of Sanofi

·     Joseph Bolen, PhD, Entrepreneur-In-Residence, PureTech; former President and Chief Scientific Officer at Moderna Therapeutics and former Chief Scientific Officer and Global Head of Oncology Research at Millennium

·     Marko Ahtisaari, CEO and Co-Founder of the Sync Project

·     Bernat Olle, PhD, CEO of Vedanta Biosciences

·     Jan Skvarka, President, CEO of Tal Medical

·     Eddie Martucci, PhD, CEO of Akili Interactive Labs

·     Additional members of the PureTech leadership team

If you would like to attend the event, please contact [e-mail].

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is a cross-disciplinary healthcare company developing innovative products that could improve the lives of billions of patients. PureTech is focused on areas of growing scientific and technical insights that it believes are at an important inflection point, including the central nervous, gastro-intestinal and immune systems, and the interactions and signalling between them. PureTech has a pipeline of more than 30 programmes and has approximately 20 clinical studies across its pipeline, targeting multi-billion dollar market opportunities. PureTech's advanced programmes include five with human proof-of-concept and multiple with pivotal or registration study readouts in the next two years. PureTech's leading team and board, along with an advisory network of more than 60 expert founder-scientists and advisors across multiple disciplines, gives PureTech access to potentially ground-breaking science and technological innovation. With healthcare undergoing major transformation, PureTech believes it is well positioned to develop and launch medicines for the 21st century. For more information, visit http://www.puretechhealth.com and connect with us on Twitter.

Enquiries

PureTech Julie DiCarlo, Senior Vice President, Communications and Investor Relations	+1 617 226.4819
FTI Consulting (Communications adviser to PureTech) Ben Atwell Matthew Cole	[phone]

 

END

 

 

NRAGGUQGAUPQUAU